Two large strategic acquisitions led the day, with Italy's Angelini Pharma agreeing to buy Catalyst Pharmaceuticals for $4.1 billion to enter the U.S. rare disease market, and Roche acquiring PathAI for up to $1.05 billion to deepen its AI-driven diagnostics capabilities. On the regulatory front, the FDA agreed to reconsider Pierre Fabre's twice-rejected Ebvallo (tabelecleucel) for EBV+ post-transplant lymphoproliferative disease following a Type A meeting. Meanwhile, EnGene's shares fell roughly 80% on updated Phase 2 LEGEND data for detalimogene voraplasmid in non-muscle invasive bladder cancer, underscoring the continued volatility in clinical-stage biotechs.
Top Stories
Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion
Italian pharma group Angelini has entered a $4.1 billion agreement ($31.50 per share in cash, a 28% premium to the 30-day VWAP through April 22, 2026) to acquire Catalyst Pharmaceuticals, securing the biotech's rare neuromuscular and neurology portfolio including commercial asset Firdapse (amifampridine) for Lambert-Eaton myasthenic syndrome, PharmExec and STAT report. The transaction — backed in part by Blackstone funds and expected to close in the third quarter of 2026 — represents Angelini's entry into the U.S. market and a significant consolidation play in the orphan drug space. This signals continued appetite for revenue-generating rare disease assets despite broader market uncertainty.
Roche Acquires AI Diagnostics Leader PathAI for Up to $1.05 Billion
Roche has agreed to acquire PathAI for up to $1.05 billion ($750 million upfront plus up to $300 million in milestones), upgrading a partnership originally established in 2021 into full ownership of the AI-powered digital pathology platform, with the transaction expected to close in the second half of 2026 subject to customary regulatory approvals, per a Roche release. The acquisition strengthens Roche's Diagnostics division and positions the company at the intersection of precision medicine and artificial intelligence. Worth watching because Roche is betting that AI-assisted pathology will become table stakes for companion diagnostics and patient stratification.
GSK Commits $1 Billion for SiranBio's Metabolic Oligonucleotide
GSK has entered a licensing deal worth up to $1 billion with SiranBio to secure rights to SA030, an oligonucleotide targeting metabolic disease complications, according to Pharmaceutical Technology. The agreement aligns with GSK's strategic focus on obesity-related complications while addressing upcoming patent expiries in its portfolio. This signals GSK's urgency to replenish its pipeline with differentiated assets in high-growth metabolic categories.
Blackstone Invests $250 Million in Anagram for Oral Enzyme Replacement Therapy in Pancreatic Insufficiency
Blackstone Life Sciences is deploying $250 million into Anagram Therapeutics to fund pivotal development, approval and launch of ANG003, a novel oral recombinant enzyme replacement therapy for exocrine pancreatic insufficiency due to cystic fibrosis (and related disorders including pancreatic cancer), Endpoints News reports, with deal terms outlined in a Blackstone Life Sciences release. The therapy aims to reduce a daily pill burden that can reach 40 capsules with current pancreatic enzyme products. The move suggests confidence that substantial value remains in addressing CF-adjacent disease burden even as Vertex's CFTR modulators dominate the broader CF market.
FDA to Reconsider Pierre Fabre's Ebvallo for EBV+ PTLD After Two Prior Rejections
Following a Type A meeting, the FDA has agreed to reconsider whether the Phase 3 ALLELE single-arm data can support approval of Ebvallo (tabelecleucel), an allogeneic T-cell therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), after two prior complete response letters (most recently on January 9, 2026), according to STAT and Endpoints News. Atara Biotherapeutics transferred the BLA to Pierre Fabre Pharmaceuticals in November 2025, and the companies have reached agreement with regulators to address the primary concerns. This signals the FDA may be willing to revisit rare disease decisions when sponsors provide compelling additional context.
EnGene Shares Plunge ~80% on Updated Phase 2 LEGEND Data for Detalimogene Voraplasmid in NMIBC
Canadian biotech EnGene saw its stock collapse roughly 80% on May 7, 2026, after releasing updated pivotal Phase 2 LEGEND data for detalimogene voraplasmid, a non-viral gene therapy in high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), according to Endpoints News, with company-disclosed efficacy and safety details available via a company release. The market reaction reflected investor concern about the therapy's commercial trajectory despite the asset holding RMAT designation. Worth watching because NMIBC remains an area of high unmet need despite recent IO and gene therapy entrants.
Incyte Reports Week 24 TRuE-AD4 Data for Opzelura in Moderate Atopic Dermatitis
Incyte announced 24-week long-term results from its Phase 3 TRuE-AD4 trial of Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis, with 84.3% achieving EASI75 and 70.6% achieving IGA Treatment Success at Week 24, PharmExec reports, with full data presented at the EADV Symposium May 7-9, 2026 (per an Incyte release). The topical JAK inhibitor is already approved for AD, and these longer-term data support an EU Type-II variation submission for moderate AD. This signals Incyte's commitment to building durability data to defend market share against emerging oral therapies.
Bayer Prepares Regulatory Filings for AT-01 (Iodine-124 Evuzamitide) PET Tracer in Cardiac Amyloidosis
Armed with positive Phase 3 REVEAL data on sensitivity and specificity, Bayer is preparing regulatory submissions for AT-01 (iodine-124 evuzamitide) — a pan-amyloid PET tracer with FDA Breakthrough Therapy Designation, licensed from Attralus in January 2026 — designed to accelerate diagnosis of cardiac amyloidosis, pharmaphorum reports. Earlier and more accurate diagnosis could meaningfully shorten the typical two-to-four-year delay between symptom onset and diagnosis and support uptake of recently approved therapies. The move suggests diagnostics companies see opportunity in rare cardiovascular indications as therapeutic options expand.
EMA Issues 2026/2027 Seasonal Influenza Vaccine Strain Recommendations
The European Medicines Agency has published strain recommendations for the 2026/2027 seasonal influenza vaccine, covering both egg-derived and live-attenuated formulations, according to an EMA announcement. The guidance enables vaccine manufacturers to begin production cycles for next season's supply across Europe. This signals regulatory preparation for potential supply chain improvements after recent seasonal vaccine shortages.
Family Office Healthcare Investments Rebound Sharply in April
Healthcare startups captured nearly a third of family office investments in April, marking a significant rebound in deal-making activity, CNBC reports. The renewed interest from ultra-high-net-worth investors suggests improving sentiment toward biotech fundamentals despite public market volatility. Worth watching because family offices often move ahead of institutional capital when sector sentiment shifts.
What to Watch
- Rare disease M&A momentum: Angelini's $4.1B Catalyst acquisition and continued rare disease deal flow suggest strategic acquirers see durable value in orphan assets despite broader market headwinds.
- AI diagnostics consolidation: Roche's $1.05B PathAI purchase may catalyze further acquisitions as pharma majors race to integrate AI-powered precision medicine capabilities into drug development and companion diagnostics.
- FDA rare disease flexibility: The agency's willingness to reconsider Ebvallo after two rejections could signal more collaborative regulatory pathways for challenging rare disease programs with limited development options.
- CF-adjacent disease burden: Blackstone's $250M Anagram investment in oral enzyme replacement therapy for exocrine pancreatic insufficiency highlights emerging interest in residual disease burden that persists even after transformative CFTR modulator therapy, potentially opening a new market segment.
Market Snapshot
- Private capital rotation: Family offices increased healthcare allocation to 33% of April investments, suggesting institutional-quality private capital is returning ahead of public biotech indices.
- Mega-deal pipeline restocking: GSK's $1B SiranBio deal and Angelini's $4.1B Catalyst acquisition demonstrate large pharma willingness to deploy significant capital to address patent cliffs and portfolio gaps.
- Clinical volatility persists: EnGene's 80% single-day decline on Phase 2 data underscores ongoing binary risk in development-stage assets, particularly in crowded oncology indications where differentiation is difficult to achieve.